BCAX vs BCTXZ

Bicara Therapeutics Inc. vs BriaCell Therapeutics Corp. War — Valuation Comparison 2026

BCAX

Pharmaceutical Preparations
Bicara Therapeutics Inc.
Quality
4.3
out of 10
Value Trap
12
SAFE
Price
$21.75
Last close
Models
7/13
Active
VS

BCTXZ

Pharmaceutical Preparations
BriaCell Therapeutics Corp. War
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$0.08
Last close
Models
1/13
Active

Model-by-Model Comparison

ModelType BCAX Fair ValueBCAX Upside BCTXZ Fair ValueBCTXZ Upside
Bayesian DCF Intrinsic $8.09 -62.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.41 -84.3% $0.31 +227.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCAX vs BCTXZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCAX vs BCTXZ — Which Stock Is More Undervalued?

BCTXZ scores higher with a 4.4/10 quality rating vs BCAX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bicara Therapeutics Inc. (BCAX) and BriaCell Therapeutics Corp. War (BCTXZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCAX currently trades at $21.75 with a QOC of 4.3/10, while BCTXZ trades at $0.08 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).